Inside Canada's Cannabis Export Machine: How LPs Crack the EU Market

Photo by Arum Visuals via Unsplash.

Nobody drafting Canada's Cannabis Act in 2018 was thinking about German pharmacy shelves. The law was built for a domestic recreational market -- retail stores, provincial distributors, a THC-tracking seed-to-sale system meant to keep product inside Canadian borders. Yet eight years later, Canada supplies roughly half of the medical cannabis flower imported into Germany, a country of 84 million people with essentially no domestic cultivation capacity to speak of. That's not a rounding error. It's a trade corridor that grew almost by accident, then got formalized into something Canadian licensed producers now build entire business strategies around.

The mechanics matter more than the headline number. Germany allows medical cannabis. Canada allows commercial export. On paper that sounds like a straightforward match -- two countries, both comfortable with cannabis as medicine, doing business. In practice, getting a kilogram of dried flower from a greenhouse in British Columbia into a pharmacy in Bavaria requires clearing a bilateral permit system that treats every shipment as its own event, plus a manufacturing standard considerably stricter than anything Health Canada demands of producers selling at home. Legality in both countries is the starting point, not the finish line.

Germany's Supply Gap and Canada's Response

Photo by Terrance Barksdale via Pexels.

The numbers tell a fairly stark story about scale. Germany imported 201,094 kilograms of medical cannabis flower in 2025, and Canadian producers accounted for 93,006 kg of that -- about 46%. The pace hasn't slowed. In the first quarter of 2026 alone, Germany brought in 50,539 kg, with Canadian flower making up 53% of that total, an even larger share than the year before. For a country with only three domestic licensed producers, that dependency isn't surprising -- it's structural. Three companies simply cannot grow, process, and distribute enough medical-grade cannabis for a population the size of Germany's, especially as prescription volumes climb and more physicians treat cannabis as a mainstream therapeutic option rather than a last resort.

Canadian licensed producers didn't stumble into this opportunity so much as build toward it deliberately. Years of oversupply in Canada's recreational market -- more licensed cultivation space than the domestic market could absorb, followed by relentless price compression at retail -- pushed larger producers to look outward for margin. Export to a market like Germany, where medical cannabis is reimbursed through statutory health insurance and priced accordingly, offered something the Canadian recreational shelf increasingly couldn't: a buyer willing to pay for pharmaceutical-grade product. That reality reshaped capital allocation across the sector, with the more well-funded operators redirecting investment toward EU-GMP-certified facilities specifically built for export rather than expanding domestic capacity nobody needed more of.

Why a Legal Export Requires Two Governments to Agree

Photo by Tima Miroshnichenko via Pexels.

Here's the part that trips up newcomers to this space: dual legality buys you almost nothing on its own. A shipment of cannabis flower can only leave Canada and land in Germany once two separate federal regulators sign off on the same transaction. Health Canada has to issue an export permit. Germany's Federal Institute for Drugs and Medical Devices -- BfArM -- has to issue a matching import permit. Both documents need to reconcile on quantity, product form, and the specific destination facility receiving the goods. Mismatch any of those details and the shipment doesn't move, regardless of how much paperwork either side has already filed.

There's no such thing as a standing authorization here, even between two companies that have done this exact transaction a dozen times before. Every shipment gets its own bespoke approval, from scratch, every time. The application itself requires detailed transit and shipment information along with an attestation from a designated responsible person at the exporting facility, confirming the product meets the destination country's requirements. Health Canada generally targets a 30-business-day processing window for these applications, though real-world timelines shift depending on application completeness and how busy the review queue is.

What makes the whole system workable at commercial scale is a set of Mutual Recognition Agreements between Health Canada and EU regulatory bodies. These agreements let GMP-certified Canadian facilities skip a redundant re-inspection at the German border -- German authorities accept Health Canada's certification of EU-GMP compliance rather than sending their own inspectors to Canada for every shipment. Without that mutual recognition framework, the current volume of trade simply wouldn't be logistically possible.

GPP Won't Cut It: The EU-GMP Certification Wall

Canada supplied nearly half of Germany's medical cannabis imports in 2025 (93,006 kg of 201,094 kg total), and its dominance grew further in Q1 2026, accounting for 53% of the 50,539 kg imported.

This is where a lot of Canadian producers hit a wall they didn't see coming. Health Canada's domestic standard, Good Production Practices under Part 5 of SOR/2018-144, sets the baseline for legally selling cannabis inside Canada -- and it's a real standard, with facility, testing, and quality-control requirements. But it isn't remotely equivalent to EU-GMP, the pharmaceutical manufacturing standard the European Union requires for medicine entering its supply chain. EU-GMP is built around documentation depth, batch-to-batch repeatability, and process control at a level closer to how insulin or vaccines get manufactured than how a typical Canadian dispensary product gets made.

Health Canada doesn't require EU-GMP certification for anything sold domestically -- it's entirely voluntary, and the only reason a producer pursues it is to sell into Europe. That voluntary nature matters because certification isn't cheap or fast. Industry estimates put the cost of achieving EU-GMP certification somewhere between CAD$200,000 and $600,000 per facility, with timelines that vary considerably depending on how close a facility's existing infrastructure is to the standard before the process even starts. Some producers retrofit relatively quickly; others discover their entire production line needs rebuilding.

The result is a genuinely narrow field. As of late 2023, only 23 Canadian facilities held EU-GMP registration -- and every single one belonged to a publicly traded company. No privately held Canadian producer had spare EU-GMP capacity available to export. That's not a coincidence. Certification at this cost and complexity requires the kind of capital access that mostly comes from public markets, which has effectively turned EU export into a game reserved for a small handful of well-capitalized players rather than something the broader Canadian industry can participate in.

The Certification Pathways: Inspections, Processors, and GACP Flower

Photo by Petr via Unsplash.

Producers who do pursue EU-GMP certification generally take one of two routes. The first is inviting a willing EU member-state regulatory authority to fly to Canada and conduct the inspection directly on Canadian soil. Germany's BfArM, Portugal's Infarmed, and Denmark's DKMA have all done exactly this, sending inspectors overseas to certify Canadian facilities against the EU standard in place rather than requiring the facility to relocate or rebuild inside Europe. The second route is partnership-based: a Canadian producer grows the raw cannabis, then ships it to a licensed EU-based site that handles further processing -- milling, packaging, quality testing -- to bring the finished product up to EU-GMP standard before it ever reaches a pharmacy shelf.

That second model has actually become the more common path for the industry as a whole, and it's worth understanding because it explains a lot about how this supply chain really works. Many European buyers don't source EU-GMP-certified cultivation at all. Instead they import flower grown under GACP -- Good Agricultural and Collection Practice -- a considerably lower agricultural-cultivation bar than EU-GMP, then route that flower through EU-GMP-certified processing facilities located in Canada, Portugal, the Czech Republic, Malta, and Switzerland. GACP governs how the plant is farmed; EU-GMP governs how the raw material becomes a finished pharmaceutical product. The processing step is where the compliance gap actually gets closed.

Put together, a single gram of flower sitting in a German pharmacy may have started on a Canadian farm operating under GACP-level cultivation standards, traveled to a separately certified EU-GMP processing facility, and crossed two distinct customs and regulatory regimes before a patient ever picked up their prescription. It's a layered, multi-jurisdictional supply chain hiding behind what looks, from the pharmacy counter, like a simple import.

Ottawa Leans In on Trade Support

Photo by Werner Pfennig via Pexels.

The Canadian federal government has started treating this corridor as worth actively cultivating rather than just permitting from a distance. On May 4, 2026, representatives from the Canadian cannabis industry sat down with the Parliamentary Secretary to the Minister of International Trade alongside officials from the Canada Trade Commissioner Service. The conversation centered on export market opportunities, with industry representatives pushing to formalize government backing for further EU expansion rather than leaving companies to navigate BfArM and other European regulators entirely on their own.

That meeting fits a broader pattern that's been building for a while: Canadian trade officials increasingly talk about cannabis exports in the same register they'd use for wheat, canola, or pharmaceuticals -- as a legitimate agricultural and pharmaceutical export category rather than something to handle quietly at arm's length. Industry groups have specifically lobbied for streamlined permit processing on the Canadian side and clearer signals of federal support, arguing that competition from other GACP and EU-GMP source countries is intensifying and Canada can't assume its current market share is permanent.

What's emerged from all this is a genuine two-tier industry. On one side sit maybe two dozen well-capitalized, publicly traded producers with EU-GMP certification, servicing a German medical market that pays real prices for pharmaceutical-grade flower. On the other side sits everyone else -- smaller and privately held producers still competing in an oversupplied Canadian recreational market where margins have been ground down for years. The certification wall isn't a temporary bottleneck; it's a structural feature that determines which companies get access to the more profitable half of the business.

Germany's underlying supply gap isn't closing anytime soon. Three domestic producers can't scale up fast enough to meaningfully dent import dependency, and there's no indication that's changing in the near term. That gives Canadian exporters a durable position in this corridor, at least until other GACP-growing, EU-GMP-processing countries -- Portugal and Australia are the two most often mentioned as rising competitors -- build out comparable capacity and relationships with European regulators. For now, Canada's head start and its established Mutual Recognition Agreements are real advantages.

The thing worth watching isn't the trade numbers, which will likely keep climbing regardless. It's whether Ottawa's trade engagement -- the meetings, the Trade Commissioner Service involvement, the industry lobbying -- actually shortens permit processing times or loosens any of the bureaucratic friction described above. That's the one lever available to a government that doesn't control EU regulation but does control how quickly Health Canada moves paperwork through its own system. If that turnaround improves, it's a real policy win for exporters. If the meetings stay symbolic, the corridor keeps growing anyway, just slower than it could.